Jang Bae Moon

Dr. Jang Bae Moon


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
HJHye M Jin
Hye M Jin
TKTae-Hwan Kim
Tae-Hwan Kim
JCJung-Ho Choi
Jung-Ho Choi
MKMoon-Ju Kim
Moon-Ju Kim
YCYoung-Nan Cho
Young-Nan Cho
YPYong-wook Park
Yong-wook Park
Gout is characterized by episodes of intense joint inflammation in response to intra-articular monosodium urate monohydrate (MSU) crystals. miR-155 is crucial for the proinflammatory activation of human myeloid cells and antigen-driven inflammatory arthritis. The functional role of miR-155 in acute gouty arthritis has not been defined. Therefore, the aim of this study was to examine the role of miR-155 in pathogenesis of acute gouty arthritis.

17 February 2025 in Clinical Nuclear Medicine
Verified
Journal Article
Open access
GSGa-young Song
Ga-young Song
HJHo Cheol Jang
Ho Cheol Jang
MKMihee Kim
Mihee Kim
SASeo-Yeon Ahn
Seo-Yeon Ahn
SJSung-Hoon Jung
Sung-Hoon Jung
DYDeok-Hwan Yang
Deok-Hwan Yang
Purpose of the Report: The usefulness of brain 18F-FDG PET/CT in primary central nervous system lymphoma (PCNSL) remains underexplored. This study investigated whether early metabolic responses in interim brain FDG PET/CT serve as a prognostic indicator of PCNSL treatment outcomes. Patients and Methods: This prospective study included 53 patients with PCNSL who underwent a high-dose methotrexate–based treatment. Brain FDG PET was performed at diagnosis (baseline PET) and after induction chemotherapy (interim PET), assessing interim PET parameters such as the highest maximum standardized uptake value (hSUVmax), sum of SUVmax (sumSUVmax), highest tumor-to-normal ratio (hTNRmax), sum of TNRmax (sumTNRmax), highest metabolic tumor volume (MTV) (hMTV), and sum of MTV (sumMTV) across all PET-positive lesions. Results: High interim hTNRmax (hazards ratio: 9.76, 95% confidence interval: 1.90–50.11, P = 0.01) was an independently significant predictor of poor progression-free survival in multivariate analysis. Patients with low interim hTNRmax (≤1.0) had a significantly longer median progression-free survival than those with high interim hTNRmax (>1.0) (25.0 vs 3.6 months, P < 0.001). Incorporating interim MRI-based clinical response assessments and hTNRmax allowed the classification of partial response subgroups with markedly different prognoses (P < 0.001). High interim hTNRmax (hazards ratio: 2.76, 95% confidence interval: 1.39–5.48, P = 0.004) was an independently significant predictor of poor overall survival in multivariate analysis. Conclusions: The hTNRmax measurement from interim brain FDG PET scans emerges as an important prognostic marker in PCNSL. These findings underscore the potential of interim FDG PET evaluations to refine response assessments and inform tailored therapeutic strategies.